Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review

SHE Kaufmann, C Lange, M Rao, KN Balaji… - The lancet Respiratory …, 2014 - thelancet.com
Tuberculosis continues to kill 1· 4 million people annually. During the past 5 years, an
alarming increase in the number of patients with multidrug-resistant tuberculosis and …
被引用次数：252 相关文章

[引用][C] Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review

SHE Kaufmann, C Lange, M Rao, KN Balaji… - The Lancet …, 2014 - pure.mpg.de
Progress in tuberculosis vaccine development and host-directed therapies—a state of the art
review :: MPG.PuRe Deutsch Hilfe Datenschutzhinweis Impressum Volltexte einbeziehen …

Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review

SHE Kaufmann, C Lange, M Rao… - The Lancet …, 2014 - pubmed.ncbi.nlm.nih.gov
Tuberculosis continues to kill 1· 4 million people annually. During the past 5 years, an
alarming increase in the number of patients with multidrug-resistant tuberculosis and …

Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review

SHE Kaufmann, C Lange, M Rao, KN Balaji… - The Lancet Respiratory …, 2014 - Elsevier
Tuberculosis continues to kill 1· 4 million people annually. During the past 5 years, an
alarming increase in the number of patients with multidrug-resistant tuberculosis and …

[引用][C] Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review

SHE Kaufmann, C Lange, M Rao, KN Balaji… - The Lancet Respiratory …, 2014 - cir.nii.ac.jp
Progress in tuberculosis vaccine development and host-directed therapies—a state of the
art review | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データを …

Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review

SHE Kaufmann, C Lange, M Rao, KN Balaji… - The Lancet …, 2014 - thelancet.com
Tuberculosis continues to kill 1· 4 million people annually. During the past 5 years, an
alarming increase in the number of patients with multidrug-resistant tuberculosis and …

Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review

SHE Kaufmann, C Lange, M Rao, KN Balaji… - The Lancet Respiratory …, 2014 - infona.pl
Tuberculosis continues to kill 1· 4 million people annually. During the past 5 years, an
alarming increase in the number of patients with multidrug-resistant tuberculosis and …
[PDF] academia.edu

[PDF][PDF] Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review

SHE Kaufmann, C Lange, M Rao, KN Balaji, M Lotze… - Lancet, 2014 - academia.edu
Tuberculosis continues to kill 1· 4 million people annually. During the past 5 years, an
alarming increase in the number of patients with multidrug-resistant tuberculosis and …

Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review

SHE Kaufmann, C Lange, M Rao… - Lancet Respiratory …, 2014 - repository.ias.ac.in
Tuberculosis continues to kill 1· 4 million people annually. During the past 5 years, an
alarming increase in the number of patients with multidrug-resistant tuberculosis and …

Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review

SHE Kaufmann, C Lange, M Rao… - LANCET …, 2014 - eprints.iisc.ac.in
Tuberculosis continues to kill 1.4 million people annually. During the past 5 years, an
alarming increase in the number of patients with multidrug-resistant tuberculosis and …